Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.

As a result of tumor heterogeneity and solid cancers harboring multiple molecular defects, precision medicine platforms in oncology are most effective when both genetic and pharmacologic determinants of a tumor are evaluated. Expandable patient-derived xenograft (PDX) mouse tumor and corresponding PDX culture (PDXC) models recapitulate many of the biological and genetic characteristics of the original patient tumor, allowing for a comprehensive pharmacogenomic analysis. Here, the somatic mutations of 23 matched patient tumor and PDX samples encompassing four cancers were first evaluated using next-generation sequencing (NGS).

Scalable Lightweight Protocol for Interoperable Public Blockchain-Based Supply Chain Ownership Management.

Scalability prevents public blockchains from being widely adopted for Internet of Things (IoT) applications such as supply chain management. Several existing solutions focus on increasing the transaction count, but none of them address scalability challenges introduced by resource-constrained IoT device integration with these blockchains, especially for the purpose of supply chain ownership management. Thus, this paper solves the issue by proposing a scalable public blockchain-based protocol for the interoperable ownership transfer of tagged goods, suitable for use with resource-constrained IoT devices such as widely used Radio Frequency Identification (RFID) tags.

Assessment and Forecast of Domestic Tourism Consumption in Russia.

The article proposes an approach to determining the volume of domestic tourism in Russia and evaluates its dynamics from 2009 to 2020. Based on the use of intersectoral modeling, the economic effects of a twofold increase in the number of trips across the country planned by 2035 are determined. To achieve this indicator, a number of measures are required to increase tourist consumption within the country.

Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment.

Glioblastoma's (GBM) aggressive growth is driven by redundant activation of a myriad of signaling pathways and genomic alterations in tyrosine kinase receptors, such as epidermal growth factor receptor (), which is altered in over 50% of cases. Single agents targeting EGFR have not proven effective against GBM. In this study, we aimed to identify an effective anti-tumor regimen using pharmacogenomic testing of patient-derived GBM samples, in culture and in vivo.